Latest Manufacturing News

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Green360 Technologies has kicked off commercial production of its low-carbon Eco-Clay cement alternative through a capital-light tolling agreement with Calix, while securing federal grant funding and a $4.5 million placement to fuel growth.

Titomic Limited is gearing up for a strategic shift to the US with a planned redomicile in H2 2026, while clinching major contracts across aerospace, defense, and rail sectors and achieving critical certifications that underpin its manufacturing ambitions.

DXN Limited posted a 47.5% revenue increase to $3.7 million in Q3 FY26, buoyed by a surge in modular data centre projects and a growing pipeline of 891 identified contracts. The company advanced its Asia-Pacific footprint through a JV in Indonesia and a Malaysian manufacturing push, while securing a $5.3 million Cable Landing Station contract in Latin America.

Alexium International Group has boosted sales to $1.03 million following its Microtek Laboratories acquisition, shifting focus to manufacturing-led growth and expanding its flame-retardant and thermal regulation product lines.

Delorean Corporation reported solid progress in Q3 FY2026, including a positive Final Investment Decision for its NSW1 Horsley Park bioenergy facility backed by $30.5 million in grants, alongside ongoing construction at its flagship SA1 Salisbury project.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

Electro Optic Systems (ASX: EOS) reported a 13% increase in contract backlog to A$518 million in Q1 2026, driven by multiple major defence orders and the opening of a new Singapore facility. The company’s cash position remains strong despite a $4 million ASIC penalty.

Yugo Metals (ASX:YUG) secured government approval for its Petrovo tenement in Bosnia, while initial drilling at Sinjakovo’s Kovacevac and Erak prospects delivered promising polymetallic results. The company also appointed Petar Tomašević as permanent CEO, positioning itself for further exploration progress.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Racura Oncology reported robust progress in Q3 FY2026, including launching a key lung cancer trial and unveiling a novel blood test for cardioprotection, supported by a solid $19.38 million cash position.

Optiscan Imaging has submitted its FDA dossier for InSpecta®, marking a crucial step toward US veterinary market entry, while progressing clinical studies for InVue® and InForm® ahead of further FDA submissions in 2026.